LPCN · Lipocine Inc.

Lipocine Inc. announced financial results for the first quarter ended March 31, 2026, reporting a GAAP net loss of $3.7 million or ($0.52) per diluted share, compared to a $1.9 million loss or ($0.35) per share in the prior year quarter. Royalty revenue from TLANDO sales increased modestly to $119,000 from $94,000, reflecting ongoing commercialization through licensing agreements with Verity Pharma for the US and Canada, and additional partners in Brazil, GCC countries, and South Korea. The net loss widened primarily due to elevated research and development expenses of $2.8 million, up from $1.1 million, driven by costs associated with the LPCN 1154 Phase 3 clinical study. General and administrative expenses edged up to $1.2 million from $1.1 million due to higher professional and consulting fees. Balance sheet strength improved with unrestricted cash, cash equivalents, and marketable securities reaching $24.7 million as of March 31, 2026, up from $14.9 million at year-end 2025, providing runway for ongoing operations. Concurrently, the company disclosed topline results from its Phase 3 trial of LPCN 1154 (oral brexanolone) for postpartum depression, which failed to meet the primary endpoint of statistically significant HAM-D score reduction at hour 60 versus placebo in the full analysis set (N=90). However, a post hoc analysis in the subgroup with psychiatric history (n=54) demonstrated significant and sustained HAM-D improvements from hour 12 through day 30. LPCN 1154 exhibited a favorable safety profile with no treatment-related serious adverse events, discontinuations, or issues like excessive sedation, supporting potential outpatient use. Lipocine has sought breakthrough therapy and fast track designations, is awaiting FDA feedback, and is evaluating paths forward including a validation study in the psychiatric subgroup, other candidates, partnerships, or strategic transactions. The company plans to present full Phase 3 data at medical conferences. Investors should note the Item 2.02 information, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act.